SG11201909973UA - Methods and compositions for treating sleep apnea - Google Patents

Methods and compositions for treating sleep apnea

Info

Publication number
SG11201909973UA
SG11201909973UA SG11201909973UA SG11201909973UA SG 11201909973U A SG11201909973U A SG 11201909973UA SG 11201909973U A SG11201909973U A SG 11201909973UA SG 11201909973U A SG11201909973U A SG 11201909973UA
Authority
SG
Singapore
Prior art keywords
international
compositions
effort
sleep apnea
pct
Prior art date
Application number
Other languages
English (en)
Inventor
D Andrew Wellman
Luigi Taranto-Montemurro
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201909973U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of SG11201909973UA publication Critical patent/SG11201909973UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201909973U 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea SG11201909973UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491504P 2017-04-28 2017-04-28
US201762558814P 2017-09-14 2017-09-14
PCT/US2018/029518 WO2018200775A1 (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
SG11201909973UA true SG11201909973UA (en) 2019-11-28

Family

ID=63918622

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201909973U SG11201909973UA (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea
SG10202111623TA SG10202111623TA (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202111623TA SG10202111623TA (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Country Status (22)

Country Link
US (3) US11123313B2 (de)
EP (1) EP3615016A4 (de)
JP (2) JP7373997B2 (de)
KR (1) KR20240042261A (de)
CN (1) CN110799181A (de)
AU (2) AU2018260666B2 (de)
BR (1) BR112019022483A2 (de)
CA (1) CA3061468A1 (de)
CO (1) CO2019013180A2 (de)
CR (1) CR20190546A (de)
DO (1) DOP2019000274A (de)
EC (1) ECSP19084058A (de)
GE (2) GEP20227387B (de)
MA (1) MA49069A (de)
MX (2) MX2019012729A (de)
MY (1) MY200172A (de)
NI (1) NI201900110A (de)
PH (1) PH12019502427A1 (de)
SG (2) SG11201909973UA (de)
UA (1) UA127759C2 (de)
WO (1) WO2018200775A1 (de)
ZA (1) ZA201907158B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3061468A1 (en) * 2017-04-28 2018-11-01 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
US11911351B2 (en) * 2018-01-30 2024-02-27 Apnimed, Inc. (Delaware) Methods for treating sleep apnea with combinations of atomoxetine and (R)-oxybutynin
CN108309261B (zh) * 2018-02-11 2020-05-22 西安交通大学 一种猝死预警方法及装置和系统
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
AU2019370091A1 (en) * 2018-10-31 2021-05-27 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
MX2021009407A (es) 2019-02-08 2021-09-10 Brigham & Womens Hospital Inc Métodos y composiciones para el tratamiento de la apnea del sueño.
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
RU2757470C1 (ru) * 2020-11-19 2021-10-18 Ренат Рашитович Ахмеров Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы
US20240075035A1 (en) * 2021-01-14 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CN116916909A (zh) * 2021-03-04 2023-10-20 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的瑞波西汀和毒蕈碱受体拮抗剂(mra)的组合
AU2022259671A1 (en) * 2021-04-16 2023-11-09 Apnimed, Inc. (Delaware) Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
KR20240021920A (ko) * 2021-06-17 2024-02-19 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제
KR20240053061A (ko) * 2021-08-31 2024-04-23 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
TW202342011A (zh) 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２－腎上腺素受體亞型Ｃ（α－２Ｃ）拮抗劑與蕈毒鹼受體拮抗劑之組合
TW202342052A (zh) * 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之ｔａｓｋ１／３通道阻斷劑與正腎上腺素再吸收抑制劑之組合
WO2023118123A1 (en) 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of an α2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
WO2023219991A1 (en) * 2022-05-13 2023-11-16 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371923A1 (en) 1999-05-20 2000-11-30 Thomas P. Jerussi Methods for treatment of asthma using s-oxybutynin
JP2003523382A (ja) * 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
US20060039867A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
CA2590802A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
EP2672972B1 (de) * 2011-01-28 2020-11-04 Pfantastic Medical Research Institute, LLC Verfahren zur behandlung von obstruktiver schlafapnoe
CA3061468A1 (en) * 2017-04-28 2018-11-01 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
US11911351B2 (en) 2018-01-30 2024-02-27 Apnimed, Inc. (Delaware) Methods for treating sleep apnea with combinations of atomoxetine and (R)-oxybutynin

Also Published As

Publication number Publication date
KR20190140019A (ko) 2019-12-18
PH12019502427A1 (en) 2020-10-05
SG10202111623TA (en) 2021-12-30
ECSP19084058A (es) 2020-01-31
GEP20247617B (en) 2024-04-25
MX2019012729A (es) 2019-12-19
EP3615016A1 (de) 2020-03-04
AU2018260666A1 (en) 2019-11-14
GEP20227387B (en) 2022-06-10
MX2022010349A (es) 2022-09-19
US20210401777A1 (en) 2021-12-30
MA49069A (fr) 2020-03-04
AU2018260666B2 (en) 2022-07-21
EP3615016A4 (de) 2021-02-24
BR112019022483A2 (pt) 2020-05-12
CR20190546A (es) 2020-04-08
US11123313B2 (en) 2021-09-21
AU2022241471A1 (en) 2022-10-27
WO2018200775A1 (en) 2018-11-01
NI201900110A (es) 2020-03-18
KR20240042261A (ko) 2024-04-01
MY200172A (en) 2023-12-12
JP2023139000A (ja) 2023-10-03
US20200054583A1 (en) 2020-02-20
CN110799181A (zh) 2020-02-14
CA3061468A1 (en) 2018-11-01
NZ758564A (en) 2023-12-22
ZA201907158B (en) 2021-09-29
JP2020517719A (ja) 2020-06-18
CO2019013180A2 (es) 2020-02-07
DOP2019000274A (es) 2019-12-30
JP7373997B2 (ja) 2023-11-06
UA127759C2 (uk) 2023-12-27
US20240189261A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
SG11201909973UA (en) Methods and compositions for treating sleep apnea
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201906412SA (en) Pyridine compounds as allosteric shp2 inhibitors
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201906417RA (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906163TA (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201907334QA (en) Therapeutic dendrimers
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201909466RA (en) Human anti-semaphorin 4d antibody
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same